Chronic lymphocytic leukemia (CLL), a low-grade malignancy of B lymphocytes, is a common malignancy in developed nations, with approximately 1100 new cases in Australia each year, 3500 in the United Kingdom, and 20,110 in the United States of America. With high 5-year survival rates of 76.7%(75.1–78.2%), the development of second cancers,either associated with the disease or as sequelae to treatment or shared risk factors, becomes a significant consideration. This issue is further compounded with the background risk of an older patient population, with the mean age of CLL onset 70 years. Skin cancer is one of the most common cancers globally, with one in every three new cancers diagnosed being a skin cancer. This is of particular importance in Australia, which has the second highest incidence of skin cancer in the world (having recently been overtaken by New Zealand).